• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » ZimVie launches duo of dental offerings

ZimVie launches duo of dental offerings

June 16, 2022 By Sean Whooley

ZimVieZimVie (Nasdaq:ZIMV) announced today that it launched the T3 Pro tapered implant and Encode emergence healing abutment.

Westminster, Colorado-based ZimVie designed the T3 Pro to deliver high primary stability and immediate function with a hybrid surface featuring its proprietary Osseotite surface on the implant collar, superimposed on the grit-blasted implant body. T3 Pro represents the latest addition to the T3 family of implants.

T3 Pro has demonstrated safety, performance and a positive effect of the Osseotite surface in preserving crestal bone, while the hybrid surface with the optional integrated platform switching design provides early and long-term peri-implant bone support, according to a news release. Finally, the implant’s modernized collar design for placement depth adjustment and self-tapping threads for controlled insertion boost surgical performance, ZimVie said.

ZimVie’s Encode emergence healing abutment was designed to provide clear intraoral scans and aesthetics for patient comfort and healing. The 3-in-1 healing abutment, impression coping and scan-body offer efficiency by reducing the need for multiple abutment removals in the treatment process while improving hard and soft tissue preservation.

The company redesigned emergence profiles on the abutment to facilitate natural gingival tissue healing for improved aesthetics. The Encode abutment has intuitive, unique codes on the top surface and a matte appearance to allow for clear intraoral scanning and strong restoration precision.

ZimVie said the two FDA-cleared dental offerings “reflect significant innovation” to its previous products and provide an optimized implant experience for both dentists and patients. The commercial rollout for the devices will begin in the U.S. with the intention of expanding to additional countries pending necessary regulatory approvals.

“We are excited to launch the next evolution in our T3 family of implants and Encode impression system, which has been used in more than two million implant restoration procedures to date,” ZimVie SVP and President of ZimVie Dental Indraneel Kanaglekar said in the release. “ZimVie is committed to providing innovative treatment options to improve patient care while partnering with dental professionals globally to advance dental technology and end-to-end workflow solutions.”

Filed Under: Business/Financial News, Dental, Featured, Implants Tagged With: ZimVie

More recent news

  • Former Shockwave Medical CEO joins Solenic Medical’s board
  • Anaconda Biomed brings in $56 million
  • Precision Neuroscience raises $250M in Series D for its BCI
  • Fresenius discontinuing Chinese sales of 4008A hemodialysis system
  • Perfuze’s super-bore stroke catheter tops conventional, cyclic aspiration in bench study

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy